I want to congratulate Ozaki and colleagues [1] in which the authors evaluated the duration of ovarian function suppression (OFS) and the impact of the duration of OFS on the DFS in premenopausal women with hormone receptorpositive breast cancer. Their retrospective data showed that among premenopausal women with hormone receptor-positive breast cancer who received tamoxifen (TAM) + OFS as adjuvant endocrine therapy, there was no significant difference in the DFS between the OFS ≤ 3-year group and OFS > 3-year group. NCCN guidelines commonly recommend 5 years of aromatase inhibitors with ovarian suppression, especially for younger patients under the age of 35. NCCN guidelines also commonly recommend tamoxifen and ovarian suppression [2]. However, duration of OFS was not optimally described. International expert consensus favored a period of 5 years of OFS, especially in patients at higher risk of relapse such as younger age (≤ 35) and/ or with HER2-positive disease [3] . The authors evaluated DFS of the patients referencing age 40. As described above, DFS might shift better in breast cancer patients younger than age 35 who received OFS > 3-year group. Since study by Ozaki et al.
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